论文部分内容阅读
来自于欧洲心脏病学会心衰年会(HF)的一份研究报告表明,心衰患者接受联合药物治疗的品种数量不会影响其用药剂量。法国Saint Antoine医院的心脏病专家、高级研究员Patrick Assyag博士报道说,研究表明心衰药物之间的相互影响微乎其微,因此医生可调整剂量以最大限度地控制心衰而无须过多地考虑药物间的毒副作用。Patrick Assyag博士及其研究小组通过调查以了解患者究竟使用多少种治疗左心室收缩障碍的药物更为合适以及这些药物的联合治疗是否会影响其药物剂量的选择。研究人员在2004年9月～2005年3月期间对1917例左心室射血分数小于40%、纽约心脏学会(NYHA)心功能评估标准为Ⅱ～Ⅳ级的心衰患者进行了调查研究,其间共有515名心脏病
A study from the Heart Failure Society of the European Society of Cardiology (HF) shows that the number of patients receiving HFMD in heart failure does not affect their dose. Dr. Patrick Assyag, a senior researcher at Saint Antoine Hospital’s cardiologist and senior researcher in France, reports that studies show that the interaction between heart failure medications is minimal so the doctor can adjust the dose to maximize heart failure without having to think too much about medication toxic side effect. Dr. Patrick Assyag and his team conducted a survey to find out exactly how many different drugs the patient is using to treat left ventricular systolic dysfunction and whether the combination of these drugs can affect their choice of drug dosage. Researchers conducted a survey of 1917 patients with heart failure who had LV ejection fraction of less than 40% and NYHA cardiac function criteria of grade II-IV between September 2004 and March 2005 A total of 515 heart disease